Dynamic and static small-animal SPECT in rats for monitoring renal function after177Lu-labeled Tyr3-octreotate radionuclide therapy

Journal of Nuclear Medicine

Volumn 51, Issue 12, 2010, Pages 1962-1968

  Melis, Marleen ^a   De Swart, Jan ^a   De Visser, Monique ^a   Berndsen, Saskia C ^a   Koelewijn, Stuart ^a   Valkema, Roelf ^a   Boerman, Otto C ^b   Krenning, Eric P ^a   De Jong, Marion ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Animal imaging; Dynamic imaging; Micro SPECT; Nephrotoxicity; PRRT; Radionuclide therapy; Renal; Renography

Indexed keywords

LUTETIUM 177; LYSINE; MERTIATIDE TC 99M; OCTREOTIDE[3 TYROSINE]; PENTETATE INDIUM IN 111;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; CREATININE BLOOD LEVEL; FOLLOW UP; HISTOPATHOLOGY; KIDNEY FUNCTION; KIDNEY INJURY; KIDNEY SCINTISCANNING; MALE; NEPHROTOXICITY; NONHUMAN; PRIORITY JOURNAL; PROTEIN URINE LEVEL; RADIOACTIVITY; RAT; RENAL PROTECTION; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY;

ALBUMINS; ANIMALS; AUTORADIOGRAPHY; CREATININE; GLOMERULAR FILTRATION RATE; KIDNEY; KIDNEY DISEASES; KIDNEY TUBULES; LYSINE; MALE; OCTREOTIDE; ORGANOMETALLIC COMPOUNDS; PENTETIC ACID; PROTEINURIA; RADIATION INJURIES; RADIOISOTOPE RENOGRAPHY; RADIOPHARMACEUTICALS; RATS; RATS, INBRED LEW; TECHNETIUM TC 99M DIMERCAPTOSUCCINIC ACID; TECHNETIUM TC 99M MERTIATIDE; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON;

EID: 78651279251     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: 10.2967/jnumed.110.080143     Document Type: Article

References (38)

1. Franc BL, Acton PD, Mari C, Hasegawa BH. Small-animal SPECT and SPECT/CT: important tools for preclinical investigation. J Nucl Med. 2008;49:1651-1663.
2. Nuyts J, Vunckx K, Defrise M, Vanhove C. Small animal imaging with multipinhole SPECT. Methods. 2009;48:83-91.
3. Forrer F, Rolleman E, Schramm N, Krenning EP, de Jong M. Is it possible to predict renal function in small animals using a multi-pinhole SPECT system. Eur J Nucl Med Mol Imaging. 2007;34:1127-1128.
4. Kwekkeboom DJ, de Herder WW, van Eijck CH, et al. Peptide receptor radionuclide therapy in patients with gastroenteropancreatic neuroendocrine tumors. Semin Nucl Med. 2010;40:78-88.
5. Otte A, Herrmann R, Heppeler A, et al. Yttrium-90 DOTATOC: first clinical results. Eur J Nucl Med. 1999;26:1439-1447.
6. Cwikla JB, Sankowski A, Seklecka N, et al. Efficacy of radionuclide treatment DOTATATE Y-90 in patients with progressive metastatic gastroenteropancreatic neuroendocrine carcinomas (GEP-NETs): a phase II study. Ann Oncol. 2010;21:787-794.
7. 90Y-DOTATOC. J Nucl Med. 2005;46:1310-1316.
8. 177Lu-octreotate in patients with bronchial and gastroenteropancreatic neuroendocrine tumors. J Nucl Med. 2010;51:383-390.
9. 177Lu-DOTATATE [abstract]. Eur J Nucl Med Mol Imaging. 2009;36(suppl 2):S219.
10. Rolleman EJ, Valkema R, de Jong M, Kooij PP, Krenning EP. Safe and effective inhibition of renal uptake of radiolabelled octreotide by a combination of lysine and arginine. Eur J Nucl Med Mol Imaging. 2003;30:9-15.
11. Kwekkeboom DJ, Krenning EP, Lebtahi R, et al. ENETS Consensus guidelines for the standards of care in neuroendocrine tumors: peptide receptor radionuclide therapy with radiolabeled somatostatin analogs. Neuroendocrinology. 2009;90:220-226.
12. Prasad V, Fetscher S, Baum RP. Changing role of somatostatin receptor targeted drugs in NET: nuclear medicine's view. J Pharm Pharm Sci. 2007;10:321s-337s.
13. de Jong M, Rolleman EJ, Bernard BF, et al. Inhibition of renal uptake of indium-111-DTPA-octreotide in vivo. J Nucl Med. 1996;37:1388-1392.
14. 177Lu-DOTATATE: the role of associated risk factors. Eur J Nucl Med Mol Imaging. 2008;35:1847-1856.
15. 3] octreotate for somatostatin receptor-targeted radionuclide therapy. Int J Cancer. 2001;92:628-633.
16. 3]octreotate in rats. Eur J Nucl Med Mol Imaging. 2007;34:219-227.
17. 99mTc-DMSA-SPECT and molecular imaging. Cancer Biother Radiopharm. 2007;22:40-49.
18. Maisey M. Radionuclide renography: a review. Curr Opin Nephrol Hypertens. 2003;12:649-652.
19. Durand E, Prigent A. The basics of renal imaging and function studies. Q J Nucl Med. 2002;46:249-267.
20. 99mTc-DMSA clearance a useful marker of proximal tubular dysfunction? Eur J Nucl Med. 1984;9:439-442.
21. 99mTc-DMSA uptake into the renal cortical tubular cell. Eur J Nucl Med. 1988;14:555-561.
22. Müller-Suur R, Gutsche HU. Tubular reabsorption of technetium-99m-DMSA. J Nucl Med. 1995;36:1654-1658.
23. de Lange MJ, Piers DA, Kosterink JG, et al. Renal handling of technetium-99m DMSA: evidence for glomerular filtration and peritubular uptake. J Nucl Med. 1989;30:1219-1223.
24. Forrer F, Valkema R, Bernard B, et al. In vivo radionuclide uptake quantification using a multi-pinhole SPECT system to predict renal function in small animals. Eur J Nucl Med Mol Imaging. 2006;33:1214-1217.
25. 99mTc-DMSA in patients with tubular proteinuria. Pediatr Nephrol. 2009;24:2211-2216.
26. Jouret F, Walrand S, Parreira KS, et al. Single photon emission-computed tomography (SPECT) for functional investigation of the proximal tubule in conscious mice. Am J Physiol Renal Physiol. 2010;298:F454-F460.
27. 99mTc-MAG3 via rat renal organic anion transporter 1. J Nucl Med. 2004;45:80-85.
28. 177Lu at high specific activities. Eur J Nucl Med Mol Imaging. 2003;30:917-920.
29. van der Have F, Vastenhouw B, Ramakers RM, et al. U-SPECT-II: an ultra-high-resolution device for molecular small-animal imaging. J Nucl Med. 2009;50:599-605.
30. Christensen EI, Nielsen S, Moestrup SK, et al. Segmental distribution of the endocytosis receptor gp330 in renal proximal tubules. Eur J Cell Biol. 1995;66:349-364.
31. Melis M, Krenning EP, Bernard BF, et al. Localisation and mechanism of renal retention of radiolabelled somatostatin analogues. Eur J Nucl Med Mol Imaging. 2005;32:1136-1143.
32. Leheste JR, Melsen F, Wellner M, et al. Hypocalcemia and osteopathy in mice with kidney-specific megalin gene defect. FASEB J. 2003;17:247-249.
33. Kim SE, Cho JT, Lee DS, et al. Poor renal uptake of technetium-99m-DMSA and technetium-99m-MDP in a patient with Fanconi syndrome and near normal glomerular filtration rate. J Korean Med Sci. 1994;9:29-34.
34. Mitchell JR, Verweij M, Brand K, et al. Short-term dietary restriction and fasting precondition against ischemia reperfusion injury in mice. Aging Cell. 2010;9:40-53.
35. Baum RP, Prasad V, Hommann M, Zachert C, Hoersch D. Treatment of metastasised neuroendocrine tumours with the radiolabeled somatostatin analogues Lu-177 or Y-90-DOTA-TATE: long term toxicity and survival in 543 patients [abstract]. Eur J Nucl Med Mol Imaging. 2009;36(suppl 2):S432.
36. Wessels BW, Konijnenberg MW, Dale RG, et al. MIRD pamphlet no. 20: the effect of model assumptions on kidney dosimetry and response - implications for radionuclide therapy. J Nucl Med. 2008;49:1884-1899.
37. Rolleman EJ, Melis M, Valkema R, et al. Kidney protection during peptide receptor radionuclide therapy with somatostatin analogues. Eur J Nucl Med Mol Imaging. 2009;37:1018-1031.
38. Rajic M, Ilic S, Vlajkovic M, et al. Radionuclide staging of renal function in type 1 diabetes mellitus. Ren Fail. 2007;29:685-691.